You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
On Sept 21, 2012, the Food and Drug Administration (FDA) granted tentative approval to lamivudine, nevirapine and zidovudine fixed dose combination scored tablets for oral suspension, 30 mg/50 mg/60 mg, indicated alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in children weighing 5 to 25 kg.
"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under the PEPFAR program.
Lamivudine, Nevirapine and Zidovudine is a combination of two nucleoside analog HIV-1 reverse transcriptase inhibitors (lamivudine and zidouvine) and one non-nucleoside analogue reverse transcriptase inhibitor (nevirapine).
The product is manufactured by Strides Arcolab Limited of Bangalore, India, and was reviewed under the FDA guidance titled Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously approved Antiretrovirals for the Treatment of HIV, developed to clarify the regulatory requirements that apply to such applications, possible issues of concern, and how they should be addressed. The guidance is intended to encourage sponsors to submit applications for combination and co-packaged products, and to facilitate submission of such applications to FDA.
This action represents the 153rd FDA approval or tentative approval under PEPFAR.
A complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan is available on the FDA web site.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
